Evidence map›Paper›PMID 40081951›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Radiances of Cerenkov-Emitting Radionuclides on the In Vivo Imaging System.

Edwin C Pratt, Travis M Shaffer, David Bauer, Jason S Lewis, Jan Grimm

Abstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trop-2.2-Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Edwin C PrattDepartment of Pharmacology, Weill Cornell Graduate School, New York, New York; pratte@mskcc.org grimmj@mskcc.org.
Travis M ShafferDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and.
David BauerDepartment of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jason S LewisDepartment of Pharmacology, Weill Cornell Graduate School, New York, New York.
Jan GrimmDepartment of Pharmacology, Weill Cornell Graduate School, New York, New York; pratte@mskcc.org grimmj@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Leveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2M
Smart and self-reporting clinical nano carriers for drug deliveryR01CA215700 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GRIMM, JAN · 2017 to 2021
$3.5M
Multicolor PET to interrogate cancer biologyR01EB033000 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI Jan Grimm, Vladimir Ponomarev · 2023 to 2026
$2.6M
Cerenkov 2.0 – Cerenkov-activated agents for imaging and therapyR56EB030512 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI GRIMM, JAN · 2022 to 2022
$717k
The Ivis Spectrum CT for Pre-Clinical Oncology ResearchS10OD016207 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI ZANZONICO, PAT B · 2013 to 2013
$595k
Targeting Pancreatic Cancer Senescence with ImmunoPETK99CA276804 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PRATT, EDWIN CHARLES · 2024 to 2025
$297k
Understanding tumorigenesis and metastasis of pancreatic cancer through precision whole-body imaging of senescence with ImmunoPETF32CA268912 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PRATT, EDWIN CHARLES · 2022 to 2023
$142k
NCI NIH HHS F32 CA268912NCI NIH HHS K99 CA276804NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA215700NCI NIH HHS R35 CA232130NIBIB NIH HHS R01 EB033000NIBIB NIH HHS R56 EB030512NIH HHS S10 OD016207
6 · The paper itself

Abstract

Cerenkov (or Cherenkov) luminescence occurs when charged particles exceed the phase velocity of a given medium. Cerenkov as a modality has gained interest for visualization of numerous radionuclides. However, reported Cerenkov intensities are limited or provided as theoretic fluence estimates. Here, we present the largest experimental dataset of Cerenkov-emitting radionuclides using the in vivo imaging system (IVIS Spectrum). We report Cerenkov radiances for 23 Cerenkov-emitting radionuclides, covering electrons, α-particles, and β-particles purified and in equilibrium where appropriate. Radionuclides measured include

Indexed as

RadioisotopesAnimalsMiceRadioisotopesCerenkov luminescenceoptical imagingradiotherapy

Identifiers

PMID40081951
PMCPMC12051767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.